Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Acute Respiratory Distress Syndrome: A Phase I/II Clinical Trial
Latest Information Update: 14 Feb 2024
At a glance
- Drugs DB-001 (Primary)
- Indications Adult respiratory distress syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms EXIT-ARDS
- Sponsors Direct Biologics
- 02 May 2023 Planned End Date changed from 1 Dec 2023 to 31 Dec 2024.
- 02 May 2023 Planned primary completion date changed from 2 Sep 2023 to 31 Dec 2024.
- 02 May 2023 Planned initiation date changed from 1 Sep 2023 to 1 Dec 2024.